DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer

Role of Bioinformatics Analysis in Early Differential Diagnosis of Ovarian Cancer

In order to solve the problem of early differential diagnosis of ovarian cancer, this paper proposes the role of bioinformatics analysis in early differential diagnosis of ovarian cancer. This method uses bioinformatics methods to mine the existing data in the tumor database and obtain tumor-related molecules. It is an efficient method to obtain effective biomarkers, screen signal pathway molecules, and reveal the internal mechanism of tumor occurrence and development. Using this method can greatly improve the efficiency and reliability of screening diagnosis, prognosis, and treatment targets. The results showed that 5821 new lncRNA transcripts and 4611 new lncRNA genes were identified by lncScore from the assembled transcripts. 10 new lncRNA transcripts and 174 new lncRNA genes were found to be differentially expressed in ovarian cancer.

Overexpression of DUOX2 mediates doxorubicin resistance and predicts prognosis of pancreatic cancer

BACKGROUND

Dysregulation of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) family is frequently observed in cancers and associated with their development and progression. However, the expression, role, and clinical significance of the NOX family members in pancreatic cancer remain unexplored.

METHODS

The expression levels of the 7 NOX family genes were analyzed in Gene Expression Omnibus (GEO) datasets. The messenger RNA (mRNA) expression and gene alterations were explored using The Cancer Genome Atlas (TCGA) data portal. Clinical significance analyses of the NOX family genes were conducted among pancreatic cancer patients. The expression and prognostic value of dual oxidase 2 (DUOX2) were then validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC) in an independent validation cohort. The function of DUOX2 was analyzed by gene set enrichment analysis (GSEA) and its effect on the chemosensitivity of pancreatic cancer cells was detected by Cell Counting Kit-8 (CCK-8) assay.

RESULTS

Results showed that NOX1, NOX2 (CYBB), NOX4, DUOX1, and DUOX2 were upregulated, while NOX3 and NOX5 were downregulated in pancreatic cancer tissues compared with nontumor tissues. Genomic alteration analysis demonstrated that deregulation of NOX family genes was partially caused by genomic alterations. Survival analyses showed that only DUOX2 was associated with overall survival (OS) and relapse-free survival (RFS) of pancreatic cancer patients. The DUOX2 gene was observed to be markedly overexpressed in pancreatic cancer. In the GSEA results for pancreatic cancer patients, DUOX2 was significantly associated with oxidoreductase activity acting on nicotinamide adenine dinucleotide hydrogen (NADH) or NADPH and uridine 5'-diphospho-glucuronosyltansferase (UDP) glycosyltransferase activity. Knockdown of DUOX2 in pancreatic cancer cells increased their sensitivity to doxorubicin.

CONCLUSIONS

Overexpression of DUOX2 is correlated with prognosis and recurrence in pancreatic cancer patients and acts as a good marker for pancreatic cancer course prediction; furthermore, DUOX2 might be a therapeutic target for pancreatic cancer patients.